The first drug used to target the CP/LP is recombinant or plasma-purified C1-INH, which is approved for usage in hereditary and acquired angioedema, where patients suffer from C1-INH deficiency [142]. This evidence concerns the gene CP and hyperinsulinemic hypoglycemia, familial, 4.